Injectable GHK-Cu was placed on the FDA's Category 2 list in 2023 and removed on April 15, 2026 because the nominations were withdrawn
Fiber considerations for tirzepatide (Mounjaro, Zepbound) Tirzepatide is a dual GIP/GLP-1 receptor agonist with a slightly different side effect profile than pure GLP-1 agonists
Premium vendors also invest in proper cold-chain shipping, tamper-evident packaging, and batch tracking systems
Single-receptor GLP-1 agonists engage only the GLP-1 receptor, while Zepbound, as tirzepatide, adds the GIP receptor for a second incretin mechanism
Exercise not only enhances fat loss but also improves body composition, cardiovascular fitness, and metabolic health independent of weight changes
Many programs quietly increase your monthly cost as your dose goes up over time